MN HF626

Health plan companies cannot restrict where enrollees receive services for diagnosis and treatment of rare diseases or conditions.

A rare disease or condition is defined as one affecting fewer than 200,000 persons in the United States, or affecting more than 200,000 persons where a drug has been designated under federal law (21 U.S.C. § 360bb).

Cost-sharing requirements and benefit limitations for rare disease diagnosis and treatment must not exceed those imposed on in-network medical treatment.

The requirement does not apply to coverage provided through public health care programs under Minnesota Statutes chapters 256B or 256L.

The section is effective July 1, 2021, and applies to health plans offered, issued, or renewed on or after that date.